Edition:
United Kingdom

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

14.95USD
17 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$14.95
Open
$14.75
Day's High
$14.95
Day's Low
$14.75
Volume
26,204
Avg. Vol
60,068
52-wk High
$18.55
52-wk Low
$10.77

Select another date:

Wed, Nov 15 2017

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

CORRECTED-UPDATE 2-FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - ‍announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary​

FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

BRIEF-MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO

* MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER

BRIEF-Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line

* Meridian Bioscience Inc- ‍Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B​ Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Q3 gaap earnings per share $0.01

* Meridian Bioscience reports third fiscal quarter 2017 operating results, including non-cash goodwill impairment charge, declares regular cash dividend, and reaffirms fiscal 2017 guidance excluding the effect of goodwill impairment charge

BRIEF-Co-Diagnostics Inc announces joint venture in India

* Co-Diagnostics Inc - once deal completed, cosara will have exclusive indian manufacturing rights for co-diagnostics products

Select another date: